We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 167.80 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
Allergan on Thursday said the U.S. Food and Drug Administration approved an expansion to the label for Botox, to include "the treatment of spasticity in pediatric patients two years of age and older."
The company said the label expansion includes those patients "with lower limb spasticity caused by cerebral palsy."
Botox hasn't been shown "to improve upper extremity functional abilities, or range of motion at a joint affected by a fixed contracture," the company said.
Allergan also said, "This label expansion is based on Allergan and another manufacturer selectively waiving orphan exclusivity marketing rights each company held for the use of their respective neurotoxins in the treatment of pediatric patients with spasticity caused by cerebral palsy."
Allergan is an AbbVie Inc. company.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 09, 2020 19:14 ET (23:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
